Henry Schein(US:HSIC)2024-02-27 22:33Financial Performance & Impact Factors - Worldwide sales decreased by 10.5% in Q4 2023, with total sales of $3.017 billion compared to $3.371 billion in Q4 2022 [10, 11, 14, 35, 51] - The cybersecurity incident led to an estimated reduction in sales of $350 million to $400 million, representing approximately 10% to 12% impact [10, 11, 15] - Non-GAAP diluted EPS was $0.66 in Q4 2023, a decrease of 51.1% compared to $1.35 in Q4 2022 [10, 11, 33, 51] - The cybersecurity incident impacted EPS by approximately $0.70-$0.75 per diluted share, and acquisition-related expenses & adjustments added $0.05 [10, 24] - Operating income decreased by 46.7% from $72 million to $39 million [11, 61] Segment Performance - Global Dental sales experienced a decrease of 10.2% [10, 14, 69] - Global Medical sales decreased by 14.9% [10, 14, 55] - Global Technology/VAS sales increased by 13.4% [10, 14, 29, 38, 41] - Dental Specialties sales grew by 17.2% [10, 41] Strategic Initiatives & Outlook - The company introduced 2024 Non-GAAP Diluted EPS guidance of $5.00 to $5.16, reflecting growth of 11% to 15% compared with 2023 [9, 45] - Adjusted EBITDA is expected to increase by more than 15% vs 2023 [9, 45]